Multi-omics Landscape of Interferon-stimulated Gene OASL Reveals a Potential Biomarker in Pan-cancer: from Prognosis to Tumor Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 17

PMID 39286258

Authors

Yi Liu

Runyu Yang

Mengyao Zhang

Bingyu Yang

Yue Du

Hui Feng

Wenjuan Wang

Busheng Xue

Fan Niu

Pengcheng He

Affiliations

Soon will be listed here.

Abstract

Background: OASL (Oligoadenylate Synthetase-Like), an interferon-induced protein in the OAS family, plays a significant role in anti-viral response. Studies have demonstrated its association with prognosis of certain tumors. However, the mechanism through which OASL affects tumors is unclear. A systemic pan-cancer study of OASL needs to be illustrated.

Methods: Analysis of OASL expression across 33 tumors was conducted utilizing TCGA, GTEx and CPTAC databases. COX and Log-Rank regressions were employed to calculate the prognosis. We validated the impact of OASL on apoptosis, migration, and invasion in pancreatic cancer cell lines. Moreover, we employed seven algorithms in bulk data to investigate the association of OASL expression and immune cell infiltration within tumor immune microenvironment (TIME) and ultimately validated at single-cell transcriptome level.

Results: We discovered elevated expression of OASL and its genetic heterogeneity in certain tumors, which link closely to prognosis. Validation experiments were conducted in PAAD and confirmed these findings. Additionally, OASL regulates immune checkpoint ligand such as programmed death ligand 1 (PD-L1), through IFN-γ/STAT1 and IL-6/JAK/STAT3 pathways in tumor cells. Meanwhile, OASL affects macrophages infiltration in TIME. By these mechanisms OASL could cause dysfunction of cytotoxic T lymphocytes (CTLs) in tumors.

Discussion: Multi-omics analysis reveals OASL as a prognostic and immunological biomarker in pan-cancer.

Citing Articles

Spatial transcriptome reveals histology-correlated immune signature learnt by deep learning attention mechanism on H&E-stained images for ovarian cancer prognosis.

Ng C, Wong K, Lawson B, Ferri-Borgogno S, C Mok S J Transl Med. 2025; 23(1):113.

PMID: 39856778 PMC: 11761186. DOI: 10.1186/s12967-024-06007-8.

Investigating the clinical significance of OAS family genes in breast cancer: an in vitro and in silico study.

Lu J, Yang L, Yang X, Chen B, Liu Z Hereditas. 2024; 161(1):50.

PMID: 39633486 PMC: 11619215. DOI: 10.1186/s41065-024-00353-9.

References

Yamaguchi H, Hsu J, Yang W, Hung M . Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022; 19(5):287-305. DOI: 10.1038/s41571-022-00601-9. View

Pang K, Shi Z, Wei L, Dong Y, Ma Y, Wang W . Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updat. 2022; 66:100907. DOI: 10.1016/j.drup.2022.100907. View

DallOlio F, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N . Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 19(2):75-90. DOI: 10.1038/s41571-021-00564-3. View

Stratton M, Campbell P, Futreal P . The cancer genome. Nature. 2009; 458(7239):719-24. PMC: 2821689. DOI: 10.1038/nature07943. View

Benci J, Johnson L, Choa R, Xu Y, Qiu J, Zhou Z . Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019; 178(4):933-948.e14. PMC: 6830508. DOI: 10.1016/j.cell.2019.07.019. View

Su X, Yee L, Im K, Rhodes S, Tang Y, Tong X . Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol. 2008; 49(2):184-91. PMC: 2609954. DOI: 10.1016/j.jhep.2008.04.011. View

Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A . Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021; 39(11):1497-1518.e11. PMC: 8599450. DOI: 10.1016/j.ccell.2021.10.001. View

Szeto G, Finley S . Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019; 5(7):400-410. PMC: 7467854. DOI: 10.1016/j.trecan.2019.05.010. View

Gao L, Ren R, Shen J, Hou J, Ning J, Feng Y . Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer. BMC Cancer. 2022; 22(1):1016. PMC: 9510761. DOI: 10.1186/s12885-022-10102-8. View

10.

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

11.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

12.

Brummel K, Eerkens A, de Bruyn M, Nijman H . Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2022; 128(3):451-458. PMC: 9938191. DOI: 10.1038/s41416-022-02119-4. View

13.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S . Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022; 40(6):598-610. DOI: 10.1200/JCO.21.01845. View

14.

Zhao W, Yang H, Liu L, Qu X, Ding J, Yu H . OASL knockdown inhibits the progression of stomach adenocarcinoma by regulating the mTORC1 signaling pathway. FASEB J. 2023; 37(3):e22824. DOI: 10.1096/fj.202201582R. View

15.

Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T . Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021; 6(1):72. PMC: 7896069. DOI: 10.1038/s41392-020-00449-4. View

16.

Hornung V, Hartmann R, Ablasser A, Hopfner K . OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat Rev Immunol. 2014; 14(8):521-8. PMC: 7097587. DOI: 10.1038/nri3719. View

17.

McGrail D, Pilie P, Rashid N, Voorwerk L, Slagter M, Kok M . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5):661-672. PMC: 8053682. DOI: 10.1016/j.annonc.2021.02.006. View

18.

Cao R, Yang F, Ma S, Liu L, Zhao Y, Li Y . Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Theranostics. 2020; 10(24):11080-11091. PMC: 7532670. DOI: 10.7150/thno.49864. View

19.

Liu Z, Yu X, Xu L, Li Y, Zeng C . Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol. 2022; 11(1):44. PMC: 9338491. DOI: 10.1186/s40164-022-00297-8. View

20.

Diaz-Montero C, Rini B, Finke J . The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020; 16(12):721-735. DOI: 10.1038/s41581-020-0316-3. View